Drug Profile
Research programme: parainfluenza virus therapies - BioCryst
Alternative Names: BCX-2798; Parainfluenza virus hemagglutinin-neuraminidase inhibitors - BioCryst Pharmaceuticals; Parainfluenza virus HN inhibitors - BioCrystLatest Information Update: 11 Dec 2012
Price :
$50
*
At a glance
- Originator BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action HN protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parainfluenza virus infections
Most Recent Events
- 07 Dec 2012 Discontinued - Preclinical for Parainfluenza virus infections in USA (PO)
- 17 Apr 2008 Preclinical pharmacodynamics data presented at the 21st International Conference on Antiviral Research (ICAR-2008)
- 02 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Viral Infections pharmacodynamics section